Opendata, web and dolomites

Glue2Degrade SIGNED

Therapeutic hijacking of E3 Ligases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Glue2Degrade project word cloud

Explore the words cloud of the Glue2Degrade project. It provides you a very rough idea of what is the project "Glue2Degrade" about.

immunomodulatory    efforts    degrading    ligase    unbiased    incremental    moiety    crbn    molecules    small    traditional    innovating    proteins    glues    drugs    glue2degrade    inhibition    genetics    exist    ikzf1    molecular    induce    prevalent    hijack    thereby    successful    initial    followed    identification    phenotypic    industry    conventional    imids    proteome    hypothesis    transform    erc    strategies    mechanisms    liganded    relies    protein    discovery    lenalidomide    pipeline    rationally    chimeras    cell    opening    cancer    druggable    receptors    academia    chimeric    data    characterization    engageable    elucidate    inducing    therapeutic    prime    pharmacologically    anticipated    e3    limitation    translational    selective    technologies    undruggable    global    space    protac    protacs    despite    exploited    targetable    tissue    systematically    laboratory    optimization    mgs    accessible    drug    hydrophobic    enzymes    pockets    proteomics    ligases    vivo    conduct    chemical    examples    overcome    degradation    first    orthogonal    degrade    proteolysis    600    degraders    inhibitors    promised    cooperative    binding    boost   

Project "Glue2Degrade" data sheet

The following table provides information about the project.

Coordinator
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH 

Organization address
address: LAZARETTGASSE 14 AKH BT 25.3
city: WIEN
postcode: 1090
website: http://www.oeaw.ac.at/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 1˙331˙340 €
 EC max contribution 1˙331˙340 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH AT (WIEN) coordinator 1˙331˙340.00

Map

 Project objective

Traditional drug design relies on inhibition of enzymes or receptors with accessible hydrophobic pockets. The concept of proteolysis targeting chimeras (PROTACs) promised to overcome this limitation. Following our discovery of the first PROTAC that induced selective protein degradation in vivo, this technology has seen a boost in academia and industry. Despite global research efforts, advances are so far incremental: (i) most focus is on degrading targets that can be liganded and are druggable with conventional inhibitors; (ii) currently, only 3 out of 600 E3 ligases can be exploited. Glue2Degrade aims to transform the pharmacologically targetable space of the proteome. The project is built on the hypothesis that molecular glues (MGs), non-chimeric small molecules that degrade target proteins by inducing cooperative binding to E3 ligases, are much more prevalent than anticipated. Lenalidomide and related immunomodulatory drugs (IMiDs) are prime examples of the potential of MGs. Without a specific targeting moiety, IMiDs induce cooperative binding of the E3 ligase CRBN to undruggable proteins like IKZF1/3, thereby inducing their degradation. However, no technologies exist to rationally develop MGs that hijack other E3 ligases. ERC-funding would allow us to address this limitation. Based on data generated in my laboratory, we will systematically identify novel MGs and their E3 ligases by innovating (i) phenotypic discovery strategies, and (ii) an orthogonal chemical genetics pipeline. To elucidate the mechanisms of novel MGs, we will (iii) conduct target identification via unbiased proteomics followed by (iv) chemical optimization and initial translational characterization. Glue2Degrade, if successful, will transform the engageable E3 space and identify novel MGs, thereby opening up the potential for therapeutic development of cell-, tissue-, and cancer-type specific chemical degraders for undruggable proteins.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLUE2DEGRADE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLUE2DEGRADE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More